Skip to main content

Advertisement

Figure 3 | Journal of Translational Medicine

Figure 3

From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Figure 3

Biomarkers for the survival and the clinical efficacy of vaccination. Neutrophil/lymphocyte ratio (NLR) < 3.0 and Lymphocyte-%  15% were considered as indicative factors. A and B, comparison between the favorite group and others. C, comparison of the patients with a NLR of  3 or a NLR of <3 between the HLA-A*2402-matched and -unmatched groups. D, comparison of the patients with Lymphocyte-%  15% between the HLA-A*2402 positive and negative groups. Lymphocyte (Ly)-%, the percentage of lymphocytes among the peripheral leukocytes; NLR, neutrophil/lymphocyte ratio; HLA, human leukocyte antigen; L-R, log-rank test; *the weighted log-rank tests with the Harrington-Fleming class of weights were performed and resulted in, ρ = 0, and γ = 0.5, p = 0.152; ρ = 0, and γ = 1, p = 0.064; ρ = 0, and γ = 2, p = 0.035; **the Harrington-Fleming tests were resulted in, ρ = 0, and γ = 0.5, p = 0.495; ρ = 0, and γ = 1, ρ = 0.346; ρ = 0, and γ = 2, ρ = 0.251; *** the Harrington-Fleming tests were resulted in, ρ = 0, and γ = 0.5, p = 0.114; ρ = 0, and γ = 1, ρ = 0.051; ρ = 0, and γ = 2, ρ = 0.029.

Back to article page